NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that Andrew Baum, M.D., will join the company as Chief Strategy and Innovation Officer, Executive Vice President. Dr. Baum will be a ...

Pfizer’s transition from pandemic reliance to growth in oncology and rare diseases reflects a strategic pivot, supported by recent acquisitions, despite the challenge of rising debt. Stabilization of ...

NEW YORK/LONDON, Nov 6 (Reuters) - The Pfizer (PFE.N), opens new tab and Novo Nordisk (NOVOb.CO), opens new tab battle for obesity drug developer Metsera (MTSR.O), opens new tab intensified on ...

Pfizer’s PFE 2024 revenue reached $63.6 billion, near the high end of its $61 billion-$64 billion guidance range. Management reaffirmed expectations for 2025 revenue of $61 billion-$64 billion and ...

Despite additional cost savings in 2026, Pfizer also forecasts that its adjusted earnings per share (EPS) will likely decline ...

Pfizer on Thursday said it is moving forward with a once-daily weight loss pill, danuglipron, after getting promising data from an early-stage trial, a milestone for the pharma giant hoping to enter ...

July 11 (Reuters) - Pfizer (PFE.N), opens new tab plans to move a reworked, once-a-day version of its weight-loss pill danuglipron into clinical trials later this year, the company said on Thursday, ...